VLA 84

Drug Profile

VLA 84

Alternative Names: Clostridium difficile vaccine - Valneva/GlaxoSmithKline; Clostridium difficile vaccine - Valneva/Novartis; IC-84; VLA84

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intercell
  • Developer Valneva
  • Class Bacterial vaccines; Immunotoxins; Protein-vaccines; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Clostridium-difficile-infections

Highest Development Phases

  • Phase II Clostridium-difficile-infections

Most Recent Events

  • 12 Apr 2017 Immunogenicity and safety data from a phase II study in Clostridium difficile infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017)
  • 03 Mar 2017 VLA 84 is still at phase II development stage in USA and Germany
  • 28 Feb 2017 VLA 84 is available for licensing as of 23 Feb 2017. http://www.valneva.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top